Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

In a randomized trial of patients with left-sided resectable pancreatic cancer, minimally invasive pancreatectomy showed comparable overall survival and disease-free survival to open surgery, ...

Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic ...

A phase 3 trial found that adding chemoradiotherapy (CRT) after induction chemotherapy in patients with unresectable pancreatic cancer did not extend overall survival compared to chemotherapy alone ...

Pancreatic cysts are fluid-filled sacs that can form in the pancreas. Some remain benign, while others have the potential to develop into pancreatic cancer. A recent study, which followed 257 patients ...

It's not surprising that pancreatic cancer is often referred to as a silent killer. With few early symptoms and an aggressive ...

The NCI grant is allowing Xu’s team to continue dissecting the interactions among Lfng, Notch3, and other key signaling pathways involved in PDAC initiation and progression. The goal is to translate ...

Pancreatic cancer, one of the most brutal and deadly diseases, sees approximately 10,800 new cases annually – 30 each day, in the UK – according to Cancer Research UK.It is the ...